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ABSTRACT
INTRODUCTION: The prevalence of gout among Maori is one of the highest in the world. This study 
explores the perceptions, understanding and treatment of gout among Maori.  
METHODS: A qualitative general inductive approach was used, guided by kaupapa Maori principles. 
Participants included 12 Maori aged 48–79 years with gout. Semi-structured interviews were under-
taken, taped and transcribed. Themes were identified from transcripts. 
FINDINGS: Participants described overwhelming sufferance due to gout, which was sometimes con-
sidered inevitable. All participants believed or had been informed that gout is caused by food and/or 
drink. This led to feelings of self-blame and blame from partners and employers. Whanau (family) were 
a resource for information and a support when independence was limited. Rongoa (traditional medicine) 
played a role in the lives of rural but not urban participants. Many reported stoicism, putting up with pain 
and putting others before themselves, as the ‘Maori way’. Medicines used for gout management were 
predominantly non-steroidal anti-inflammatory drugs, colchicine and prednisone, with allopurinol only 
playing a role late in the disease. Medications were often poorly understood and consequently improp-
erly used. Relationships with health professionals were important, but cultural, financial and time barriers 
impaired access and understanding. Gout had a huge, negative impact on the lives of participants. 
CONCLUSION: The quality of lives of many people with gout could be improved by better understand-
ing through educational campaigns for health professionals and the community. Culturally sensitive health 
care systems and a paradigm shift in gout management and early preventive treatment are needed. 
KEYWORDS: Drug therapy; ethnic groups; gout; health status disparities; primary health care; qualita-
tive research
Introduction
Gout is common amongst Maori, the indigenous 
population of New Zealand (NZ). The prevalence 
of gout is approximately 10% in Maori men, 
which is one of the highest rates in the world1,2 
and is associated with significant morbidity in 
Maori.3 Recent gene mapping suggests Maori may 
have a genetic predisposition to hyperuricaemia 
and gout.4 Gout requires people to be off work, 
and stops people undertaking sports and physical 
activities. Delayed preventive treatment leads to 
severe physical disability through the develop-
ment of complications.5 In addition, an increased 
risk of cardiovascular mortality has been demon-
strated amongst those with gout.6 
There is little research into the experience and 
management of gout in indigenous populations and 
whether current health care systems are adequately 
serving them. This study is one of the few that has 
investigated this topic in a culturally appropriate 
manner. This study used a ‘kaupapa Maori’ approach 
to explore Maori experiences of gout as a disease. 
Methods
This qualitative study used general inductive 
thematic analysis,7 where qualitative interviews 
were conducted with urban and rural Maori par-
ticipants who had been diagnosed with gout. The 
intention of this study was to explore perceptions 
and understanding of gout, its causes, the impact 
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on lifestyle, attitudes towards the condition, and 
the use of medicines for both symptomatic and 
preventive treatment. 
Kaupapa Maori
The study was guided by the principles of 
kaupapa Maori. This includes recognition of Te 
Ao Maori as a paradigm from which matauranga 
Maori is maintained from generation to genera-
tion, through the process of storytelling.8 This 
intergenerational transfer was often undertaken 
in wananga, or traditional Maori forums of 
education. The principle researcher acknowledged 
the importance of this theory in the engagement 
with participants. Maori terms of relevance to the 
study are defined in Table 1.
Rangatiratanga and mana motuhake of partici-
pants are recognised as kawa and tikanga passed 
down from tupuna. Similarly, the concepts of 
whakautuutu, or reciprocity, informed the engage-
ment and korero (discussion) with participants. 
As identified by Smith, kaupapa Maori research 
is a social project: it weaves in and out of Maori 
cultural beliefs and values, Western ways of 
knowing, Maori histories and experiences under 
colonialism, Western forms of education, Maori 
aspirations and socioeconomic needs, and West-
ern economics and global politics.9 
Study population
Those who identified as Maori and had a his-
tory of gout were eligible to participate. Urban 
participants were invited from the Improving 
Adherence using Combination Therapy (IM-
PACT) cardiovascular polypill trial undertaken in 
Auckland.10 Rural participants were recruited via 
a gout clinic in a rural town where the principal 
researcher worked as a clinical pharmacist. Roll-
ing recruitment continued until saturation of data 
was reached. Most interviews were conducted at 
participants’ homes, except for three participants 
who chose to be interviewed at the clinic. 
Community consultation
An important consideration was the extensive 
consultation that was undertaken in the com-
Table 1. Glossary of terms
Term Description
Kaupapa Maori Refers to a Maori subject, rationale and/or process 
specific for Maori by Maori
Te Ao Maori All aspects of the ‘Maori world’, which can include its 
values, principles and process
Matauranga Maori Maori knowledge
Rangatiratanga In a contemporary sense, this refers to chieftainship, 
power or authority
Mana motuhake A Maori term for having authority, control and self-
determination over one’s world
Kawa This derives from the ancient term ta te kawa or tangata 
te kawa, which is a pre-dawn ceremony for a new 
building. In modern Maori, the term kawa is frequently 
used to refer to rituals or protocols related to, but not 
limited to, the formal welcome of visitors on the Marae, 
which is determined by the people of a given area
Tikanga This derives from the word tika, to be correct to what 
is accepted as correct customary practice in all Maori 
contexts, not only the marae. Tikanga is the appropriate 
behaviour relevant to kawa associated with the ritual, 
which is determined by the people of the given area
Tupuna A Maori term for those ancestors from whom they have 
descended
Whakawhanaungatanga This represents a korero (discussion) of connection of 
persons through genealogy and/or kaupapa
Marae-based clinic A health setting on traditional lands
munity prior to the research. The principal 
researcher met with local general practitioners, 
Maori health providers, local Maori leaders and a 
tribal group (iwi) forum. There was much discus-
sion generated about the proposed research and 
unanimous support was given.
WHAT GAP THIS FILLS
What we already know: Gout and its complications occur disproportion-
ately among Maori, the indigenous people of New Zealand, and yet there 
appears to be a low rate of gout preventive therapy. The reasons and conse-
quences of both these observations are not well understood.
What this study adds: This study provides an insight into the experienc-
es of gout and its management amongst a group of Maori in New Zealand, 
and highlights areas where improvements could occur. Additionally, the 
method used in this study, guided by the principles of kaupapa Maori, intro-
duces a methodology that is culturally appropriate and adds richness and 
depth to the information obtained.
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Informed consent and ethical approval
Written informed consent was gained from all 
participants. Ethical approval for the interviews 
was obtained for urban recruitment (NXT Ref. 
06/06/072) and by expedited approval for rural 
recruitment from the NZ Northern X Regional 
Ethics Committee.
Interview schedule
The principal researcher undertook semi-struc-
tured interviews with open-ended questions. 
Participants were able to respond in both English 
and Maori, reflective of the participants and 
kaupapa of the research. As part of the process, 
whakawhanaungatanga was also essential in 
building the relationship with the participants. 
Thematic analysis
The principal researcher transcribed the inter-
views. Wherever possible, participants were 
sent transcripts to check for completeness and 
representativeness. Thematic analysis of tran-
scripts was undertaken by two of the researchers 
(LTK and CRE) independently, who then met to 
discuss their findings and agree on themes. On 
occasion, a third researcher (LB) was also engaged. 
Interviews continued until ‘saturation of themes’ 
was reached. 
Findings
Study population
Twelve participants took part, including four 
urban-dwelling and eight rural-dwelling partici-
pants. The ages ranged from 48 to 79 years and 
four participants were women.
Themes
The following eight themes were derived as they 
related to the research kaupapa. A summary can 
also be found in Table 2.
Overwhelming sufferance
All participants could recollect their first episode 
and the severity of gout.
Table 2. Themes identified during the interviews with selected participant quotes
Overwhelming sufferance
I just couldn’t move, my legs used to [expletive] pound. The pain was that bad you 
just wanted to cut your foot off. That’s how bad it is. It’s real bad and you can’t touch 
it, you can’t walk. You lose your appetite. You definitely can’t work. It knocks you 
right, you can’t [expletive] eat. It’s mean. It just makes you miserable.
Whanau (family)
Well it does impact [on your whanau]. They all stay clear. They know I am grumpy 
and they know to stay clear. They were like ‘oh no, here we go again’. It really 
impacts on your relationship side.
Rongoa (traditional medicine)
Rongoa rakau (the aspect of rongoa derived from plants)
Used by seven of the eight rural participants.
Wairuatanga (spirituality)
I look at disease as being spiritual and physical. You do need to understand your 
spiritual side as well. You need to understand the whole person; that wairua has 
gone wrong sometimes.
Te Taha Hinengaro (perceptions, beliefs, attitudes, thoughts and experiences)
Stoicism
You have to work through it. It’s the Maori thing. You just accept it; don’t question. 
Fatalism/inevitability
At the moment my children and my daughter they haven’t gotten gout yet but I 
always talk about it... the youngest one, he’s had it. He said ‘[expletive] mum’ and I 
say yeah but what’s some pain and discomfort for your life. 
Denial
I definitely got two sisters and a brother with the gout now. I see them limping too 
but they don’t admit they have it. Or they say they knocked their toe.
Impact: the ripple effect
I went to work and then I lost my job… Well with gout the boss said ‘you didn’t get 
that at work, you got that at home.’ I said ‘oh well stick your job’… Then I had to go 
from working outside to working inside in a factory job… I ended up being 17 years 
in it aye. That gout was always there aye. Sometimes I went to work with no boot 
aye. Boy if you got caught though aye. I didn’t want to miss work though aye cos the 
shift especially the overtime aye; the Saturdays and Sundays too.
Causality
I thought it was all my fault.
Medicines
I got upset puku (stomach) and diarrhoea and an ulcer too. It was from taking the 
aspirin and the diclofenac and the Voltaren. 
First time I heard there was a pill to prevent gout. I wish I had known before... I’m so 
proud; pleased to know there is a pill to prevent gout. If I could have saved myself 
from having gout for all these years! I’m getting old. I’m 64 now. I wish I had known 
before.
Health professional relationships
These doctors need to have a bash of gout and see what it feels like to them then 
they would see what it’s really like. I think they have no idea.
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I just couldn’t move, my legs used to [expletive] 
pound. The pain was that bad you just wanted to 
cut your foot off. That’s how bad it is. It’s real bad 
and you can’t touch it, you can’t walk. You lose 
your appetite. You definitely can’t work. It knocks 
you right, you can’t [expletive] eat. It’s mean. It just 
makes you miserable. (#9)
Whanau (family)
Whanau were significant in several ways. Firstly, 
they provided a resource in terms of information.
Information came from... my brother too. He was 
getting gout a lot and from my Mum too. She had 
bad gout. (#8)
The burden of disease of gout could also ripple 
through to whanau, having negative consequenc-
es on relationships.
I believe gout can wreck your marriage… Financial-
ly it puts a strain too, which just adds to it. Either 
you are out of work, off work or looking for work. 
Financially, it can be hard to see a doctor. When 
you go home you can be a bit too demanding. (#5)
Well it does impact [on your whanau]. They all stay 
clear. They know I am grumpy and they know to 
stay clear. They were like ‘oh no, here we go again’. 
It really impacts on your relationship side. (#9) 
Rongoa (traditional medicine)
Although rongoa is often perceived as a literal 
translation for traditional medicine derived from 
plants, its nature and extent covers almost every 
aspect of things Maori—physical and spiritual. 
With respect to gout, rongoa was largely limited 
to rongoa rakau/wai rakau, the use of traditional 
plants for healing properties. 
Rongoa rakau
None of the urban interviewees used rongoa for 
the purposes of gout, or in general. In contrast, 
seven of the eight rural interviewees used rongoa. 
Four participants described using rongoa specifi-
cally for gout in an acute situation, either with 
poultices/baths or internally, with some easing 
of symptoms. Three participants used rongoa on 
a more regular basis to support overall wellbeing, 
which they thought would also help their gout. 
Wairuatanga (spirituality)
In a traditional sense, wairua is at the centre of 
rongoa and some participants connected gout 
with wairua. 
I look at disease as being spiritual and physical. You 
do need to understand your spiritual side as well. 
You need to understand the whole person; that 
wairua has gone wrong sometimes. (#5)
Te Taha Hinengaro
Te Taha Hinengaro as a theme for this research 
refers to perceptions, beliefs, attitudes, thoughts 
and experiences, as they relate to gout.11 
Stoicism was an attitude displayed by all partici-
pants in their association with gout and its endur-
ing consequences. 
It wasn’t too bad... It was always hard to walk. To 
go to the toilet, you’re crawling on the floor to go to 
the wharepaku [toilet]. (#1)
One possible explanation given was:
You have to work through it. It’s the Maori thing. 
You just accept it; don’t question. (#4)
For some participants, there appeared to be an 
element of fatalism or inevitability that gout 
would occur.
At the moment my children and my daughter they 
haven’t gotten gout yet but I always talk about it... 
the youngest one, he’s had it. He said ‘[expletive] 
mum’ and I say yeah but what’s some pain and dis-
comfort for your life. You got to go through these 
things so I talk about these things with my children 
and with my mokopuna [grandchildren]. (#1)
For others there was a strong sense of denial. 
I definitely got two sisters and a brother with the 
gout now. I see them limping too but they don’t 
admit they have it. Or they say they knocked their 
toe. (#8)
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Participants also spoke about ‘attitude’ being a 
driver for not seeking optimal understanding or 
treatment.
Yeah well that is the other thing with our people 
too is they don’t like asking questions. (#1)
You know I think it was just my attitude. I was 
bullet proof. Yeah, just my attitude that’s all [when 
asked why he waited for 14 years before accessing a 
doctor for support]. (#7) 
When asked if they had any thoughts on what 
would be helpful in terms of treatment, the par-
ticipants had a number of ideas. One spoke of the 
need for whanau to not be afraid to ask questions 
or to learn more. Others had ideas on changing 
the paradigm of the health care service.
I didn’t like going to clinics at all. If it was a 
marae-based one, I would go and listen but that’s all 
maybe. (#7)
Making it easier to access the doctors. We are 
busy people too and there are long wait times. …
Pharmacist never spoke to me… Be great to have 
pharmacists involved in informing you what the 
medicines are that you are taking. Never had that 
explanation. (#4)
Impact
The research identified the flow-on effect of liv-
ing with gout that rippled through the lives of 
those afflicted with this condition. Participant 5 
spoke of his belief that gout was a major contrib-
utor to the dissolution of his marriage and loss 
of his job, describing the financial and personal 
burden.
Employers don’t understand because they have 
never had it. Never experience it. (#5)
I went to work and then I lost my job… Well with 
gout the boss said ‘you didn’t get that at work, you 
got that at home.’ I said ‘oh well stick your job’... 
Then I had to go from working outside to working 
inside in a factory job… I ended up being 17 years 
in it aye. That gout was always there aye. Some-
times I went to work with no boot aye. Boy if you 
got caught though aye. I didn’t want to miss work 
though aye cos the shift especially the overtime 
aye; the Saturdays and Sundays too. (#11)
Participant 10 spoke of the concern of losing his 
independence when gout in his fingers made it 
hard to turn the ignition in his car and to grip the 
steering wheel. There were many examples of a 
heavy toll on the person afflicted, both directly 
with loss of income and loss of function/mobility, 
but also through potential loss of self-esteem and 
functionality within whanau and community.
The following two themes—causality and 
medicines—captured understanding of gout and 
treatments. 
Causality
All interviewees believed or had been informed 
that gout is caused entirely by food and/or drink. 
…kai (food) is what causes gout. (#6)
Due to this underlying belief the participants as-
sumed the onus of their gout development rested 
with them. For example:
I thought it was all my fault. (#4)
Partners also perceived the participants were 
responsible for their gout and this impacted 
negatively.
 [Name] (wife) goes [expletive] nuts at me. She looks 
at me and says ‘[Expletive] here we go again’. (#9)
Most participants stated that they had heard of 
uric acid and understood there was a connection 
with crystal formation. One person had heard of 
serum uric acid levels yet did not know the sig-
nificance. Two participants felt that joint injury 
or damage had been a trigger. 
Medicines
It was many years before most participants became 
aware that gout attacks could be prevented through 
use of allopurinol. The average length of time to 
be prescribed allopurinol after first onset of gout 
symptoms was 18.3 years for the total cohort, 
excluding one participant who was yet to start. 
QUALITATIVE RESEARCH
ORIGINAL SCIENTIFIC PAPERVOLUME 5 • NUMBER 3 • SEPTEMBER 2013  JOURNAL OF PRIMARY HEALTH CARE 219
I know lots of doctors don’t give it [allopurinol] 
out. (#1)
Most had spent many years receiving sympto-
matic relief only. 
Yeah well I had the Voltaren, oh [expletive] for 
maybe 20 odd years. (#3)
But I used to take a lot of colchicine and stuff like 
that before allopurinol. Colchicine and something 
else… indomethacin, diclofenac [for 30 years] before 
allopurinol four months ago. (#2)
Some participants discussed adverse effects from 
non-steroidal anti-inflammatory medications 
(NSAIDs).
I got upset puku (stomach) and diarrhoea and an 
ulcer too. It was from taking the aspirin and the di-
clofenac and the Voltaren. (#8) [This participant was 
co-administering Voltaren and diclofenac thinking 
they were different medicines].
In addition, participants stated their pleasure and 
at times surprise that there existed a medicine 
that could prevent attacks.
First time I heard there was a pill to prevent gout. I 
wish I had known before... I’m so proud; pleased to 
know there is a pill to prevent gout. If I could have 
saved myself from having gout for all these years! 
I’m getting old. I’m 64 now. I wish I had known 
before. (#8)
One participant had his first gout attack at 23 years 
of age. He did not see a doctor for gout symptoms 
until he was 37 and did not commence allopurinol 
until he was 52 when he was admitted to hospital 
for gout ulceration requiring skin grafting. 
Doses of NSAIDs greater than recommended 
were sometimes used. 
As soon as it starts, I take two of those 100 mg 
Voltaren. I take two tablets first, then another one 
so that’s three, then another the next day. (#3)
I just sort of have a dozen of those indomethacin. (#2)
Participants discussed the sharing of NSAIDs in 
an acute situation.
I even shared all these medicines—Naprosyn, Vol-
taren, many times with whanau, with visitors. (#4)
Three participants who had been prescribed pred-
nisone described it as being very effective.
Those [attacks] were full on but if I took that 
[prednisone], and then bang it would disappear for 
another month. (#9)
Another participant described being given a ster-
oid injection in order to continue playing rugby. 
Four participants had been prescribed allopu-
rinol for longer than six months and found it 
very effective. Some participants had previous 
unsuccessful trials of allopurinol due to a lack of 
understanding. 
I got the allopurinol last year [300 mg] but I just 
got worse then. I thought I should take double the 
amount and it only got worse still. (#5)
I had heard from someone… they say ‘oh when you 
take allopurinol boy it gives you the gout’ and I was 
like ‘aye, I won’t take it.’ I did get some years ago 
and I put them up in the top of the cupboard and I 
wouldn’t take them. (#10)
Health professional relationships
How the health provider and participant engaged 
had an effect on the understanding and outcome. 
Cultural congruence helped.
When I got to Auckland hospital there was a Maori 
anaesthetist… And I said to him, ‘[Name] do you 
speak Maori?’ ‘Ae whaea’ And I say ‘good’. So I 
started talking Maori to him. (#1)
Some felt that doctors did not understand what 
gout was like.
These doctors need to have a bash of gout and see 
what it feels like to them then they would see what 
it’s really like. I think they have no idea. (#9)
Similarly cost, time and attitudes were factors 
described as barriers.
Financially it can be hard to see a doctor. (#5)
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It’s just that I didn’t like taking time off work [to go 
to a doctor]. (#7)
There was little information recalled from doc-
tors about the cause or how to prevent gout.
I don’t think they gave you enough. It kind of 
wasn’t even the basics. There were no follow-ups 
or anything and I was going regularly. There must 
have been time in there. I didn’t know about uric 
acid levels or what I should aim for. In my mind, I 
never had it explained. (#9)
One participant overall had a slightly different 
take on the situation by stating:
I think the doctors do give you some information 
but maybe it’s a lot to take in I think, or not under-
standable. (#10)
Discussion
The current health care system had not served 
the participants well. There was little informa-
tion provided effectively and little understand-
ing of cause or appropriate management of gout 
for many years. Participants (and whanau) often 
blamed themselves for the condition. There 
was no recognition of Maori genetic predisposi-
tion,12 or other possible contributing factors. 
Uric acid levels can increase in ischaemic heart 
disease or congestive heart failure, medical con-
ditions that have high prevalence in Maori.13,14 
High protein diets or excessive use of protein 
supplements in fit young athletes can also 
trigger gout.15 Furthermore, alcohol excess may 
be overemphasised in gout.16 The participants 
interviewed did not appear to be aware of this 
information, reflecting at times that they were 
apprehensive they would be prejudged on alco-
hol intake or that questioning on alcohol intake 
felt accusatory.
Participants received only acute treatment for 
their gout for an average of 18.3 years prior to 
commencing allopurinol. The participants also 
had little awareness of allopurinol as a preventive 
agent before being prescribed it. This contributed 
to a reliance on NSAIDs or prednisone as being 
the only recognised treatment. Participants also 
had little understanding of frequency and dosing 
of NSAIDs, with very high doses and inappropri-
ate use common. 
While the extreme pain and disability had a per-
sonal impact, it also extended into many aspects 
of participants’ lives, such as the ability to work, 
play sport, socialise, interact with whanau and, in 
some circumstances, maintain independence. The 
effect of loss of employment, for example, saw 
whanau unduly stressed and relationships suffer. 
All rural participants used rongoa as part of 
their ‘normal’ daily regimens or had been raised 
in a household that used rongoa. None of the 
urban participants used rongoa. Many considered 
wairua important in all aspects of health, includ-
ing the occurrence of gout. Participants dealt 
with gout in various ways, but most described 
stoicism and reluctance to trouble others. Rela-
tionships with health providers were important, 
but barriers such as cost, time and cultural mis-
match were described, which hindered seeking 
help. A reluctance to ask questions was evident, 
but the consultations did not appear to facilitate 
education in many cases. Whether information 
had been provided by health professionals or not, 
it was not deemed understandable, nor did the 
participants feel understood. The onus of health 
literacy and cultural competency should sit with 
the health professional. As such, every interac-
tion must be tapered to meet the needs of the 
consumer/patient.
Strengths and limitations
This study used a culturally relevant approach 
to investigate an issue that affects many indig-
enous and minority populations.17,18 The prin-
cipal researcher is Maori, with experience in 
working with Maori communities. Community 
consultation and use of whakawhanaungatanga 
were key to the study and to participant engage-
ment. A potential limitation of the study was 
the researcher’s passion for addressing inequities 
in health outcomes for Maori and her role as a 
health provider. Although the possibility of bias 
could be perceived, this was worked through 
with the research team in the construction of the 
questionnaire, translation of participant inter-
views and research findings. Triangulation of 
transcripts with participants and triangulation of 
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themes between researchers were also strengths 
of the study.
Comparison with the literature
The findings of this study had some similari-
ties to qualitative research conducted in other 
countries. Harrold et al.19 interviewed 26 patients 
and 15 health care providers in an attempt to 
understand suboptimal ‘urate lowering therapy’. 
The differences in thinking were marked, with 
providers believing, in general, that gout is a 
relatively straightforward condition; that patients 
know how to manage gout in both the acute and 
chronic phases; that acute treatment is always 
effective; that patients understand allopurinol is 
a long-term effective therapy and are adherent to 
treatment, and that patients have a clear under-
standing of the aetiology of gout. Patients, on the 
other hand, reported ineffective acute manage-
ment; only a superficial understanding of gout 
and progression; incomplete understanding of 
allopurinol and the need for long-term adminis-
tration; non-adherence with allopurinol and the 
need to tailor information to the patient.
In a second qualitative study, Lindsay et al.20 
explored the experience of living with gout. The 
emergent themes again identified the need for 
robust education of both medical practitioners 
and the wider public.
Whilst there are many case studies providing 
evidence of pain associated with gout,21,22 there is 
surprisingly little published qualitative research 
specifically looking at experience of pain.23 A 
recent review called for engagement with those 
experiencing pain directly stating:
The culture of young men today, their value on 
mateship, mana (self-worth), and manliness [includ-
ing stoicism in the face of severe pain], and their 
attitudes to medication and traditional versus phar-
maceutical remedies, are areas in need of further 
research, since the research base is limited.24 
With regard to the consequences of pain, there is 
published research demonstrating a decrease in 
quality of life and a loss of productivity with em-
ployment.25,26 Again these studies are limited other 
than the general and accepted view of pain and 
largely follow a survey format in which the ‘voice’ 
of those with gout is not specifically captured. 
Although much is known about the aetiology, 
pathology and prevention of gout, it remains a 
condition that is poorly managed at many levels. 
In the words of Professor Larry Edwards, speak-
ing at a 2011 NZ Rheumatology Scientific Meet-
ing: ‘We have always had the tools to treat gout 
but we do not do this well.’27 Other researchers 
describe prescription of allopurinol as being low 
according to burden of disease.28 The finding that 
participants generally were not fully aware of the 
concept of testing for uric acid is also consistent 
with international findings.29 
Implications for research and practice
The suboptimal understanding, management 
and prevention of gout suggested in this study 
are worrying. Further investigation is needed 
into the impact and management of gout among 
the general population, but particularly among 
those populations most at risk yet often least well 
served by the health care system. The burden of 
gout and other diseases in indigenous or minor-
ity populations contributes to health disparities 
and inequity. Changes to health care systems are 
needed to ensure effective, culturally appropriate 
education, appropriate management and timely 
use of urate-lowering preventive medications. A 
paradigm shift is needed, along with a substan-
tive education programme for health profession-
als, those with gout and communities.
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